News:Training in Computational Drug Design and Discovery @NIH, USA .May 22 - 25, 2018
0
0
Entering edit mode
6.6 years ago
AABI ▴ 140

computational drug design

Training in Computational Drug Design and Discovery

May 22 - 25, 2018


Where?


National Institutes of Health
9000 Rockville Pike
Building 60, Room 162
Bethesda, MD 20892, USA


Objectives

This hands-on training will introduce researchers to the concepts, methods and tools for structure and ligand based computational drug designing and discovery using the open source tools and the cloud computing facilities.

Background

Computational drug design and discovery has been a challenging task due to limitations in available computing resources. Public cloud computing facilities have dramatically changed this scenario, by bringing the most powerful computing systems within a click away, with unprecedented low cost options.

Hands-on Skills/Tools Taught

  • Ligand preparation : OpenBabel
  • Target preparation: Chimera
  • Databases: ZINC, PubChem, ChemSpider, ChEMBL, DrugBank, Binding DB
  • Docking: AutoDockTools
  • Visualization: Chimera, PyMOL
  • Structure based virtual screening: AutoDock, Dock
  • Ligand drawing & visualization : Chemdraw, Chemsketch
  • Compound library : ChemT (or DRUGSTER or FSees)
  • Descriptors : Mold2
  • QSAR : Open3DQSAR (or TEST or Coral)
  • Pharmacophore exploration : Open3DQSAR (or DRUGON or pharmacophore)
  • Ligand alignment : LIGSIFT
  • Ligand based virtual screening: LIGSIFT (or MOLA or lisica)
  • ADMET, Toxicity estimation : Toxtree (or DataWarrior)

Highlights

  • Cloud-based, high performance computing platform
  • Cloud image freely provided to participants
  • Training provided by active NIH researchers
  • Cookbook style bound manual for all exercises
  • Direct, after training support through exclusive forum membership
  • Continuing Educational Credits

For more information and registration, please visit the following page;

Information and Registration

discovery training computational-drug-design • 1.1k views
ADD COMMENT

Login before adding your answer.

Traffic: 2241 users visited in the last hour
Help About
FAQ
Access RSS
API
Stats

Use of this site constitutes acceptance of our User Agreement and Privacy Policy.

Powered by the version 2.3.6